Top

Published in:

01-06-2009 | Letter

Co-incidental increase in gene copy number of ERBB2 and LRIG1 in breast cancer

Authors: Ingrid Ljuslinder, Irina Golovleva, Roger Henriksson, Kjell Grankvist, Beatrice Malmer, Håkan Hedman

Published in: Breast Cancer Research | Issue 3/2009

Excerpt

Using fluorescence in situ hybridization (FISH), we previously showed that the LRIG1 gene had an increased copy number in 11 of 28 (39%) breast cancer tumours [1]. The LRIG1 gene (leucine-rich repeats and immunoglobulin-like domains 1) at chromosome 3p14 is a proposed tumour suppressor gene that negatively regulates various receptor tyrosine kinases, including the breast cancer proto-oncogene product ERBB2 [2, 3]. …

Available only for authorised users

Ljuslinder I, Malmer B, Golovleva I, Thomasson M, Grankvist K, Hockenstrom T, Emdin S, Jonsson Y, Hedman H, Henriksson R: Increased copy number at 3p14 in breast cancer. Breast Cancer Res. 2005, 7: R719-727. 10.1186/bcr1279.CrossRefPubMedPubMedCentral

Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, Amariglio N, Henriksson R, Rechavi G, Hedman H, Wides R, Yarden Y: LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J. 2004, 23: 3270-3281. 10.1038/sj.emboj.7600342.CrossRefPubMedPubMedCentral

Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway KL, Sweeney C: The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem. 2004, 279: 47050-47056. 10.1074/jbc.M409703200.CrossRefPubMed

Miller JK, Shattuck DL, Ingalla EQ, Yen L, Borowsky AD, Young LJ, Cardiff RD, Carraway KL, Sweeney C: Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Cancer Res. 2008, 68: 8286-8294. 10.1158/0008-5472.CAN-07-6316.CrossRefPubMedPubMedCentral

Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne N, Redon R, Bird CP, de Grassi A, Lee C, Tyler-Smith C, Carter N, Scherer SW, Tavaré S, Deloukas P, Hurles ME, Dermitzakis ET: Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science. 2007, 315: 848-853. 10.1126/science.1136678.CrossRefPubMedPubMedCentral

Title: Co-incidental increase in gene copy number of ERBB2 and LRIG1 in breast cancer
Authors: Ingrid Ljuslinder
Irina Golovleva
Roger Henriksson
Kjell Grankvist
Beatrice Malmer
Håkan Hedman
Publication date: 01-06-2009
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 3/2009
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr2248

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2009

Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer

WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth

Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?

Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?

Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors

A constant risk for familial breast cancer? A population-based family study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer